Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
J Neurooncol. 2019 Apr;142(2):211-221. doi: 10.1007/s11060-019-03104-3. Epub 2019 Jan 17.
Incidental discovery accounts for 30% of newly-diagnosed intracranial meningiomas. There is no consensus on their optimal management. This review aimed to evaluate the outcomes of different management strategies for these tumors.
Using established systematic review methods, six databases were scanned up to September 2017. Pooled event proportions were estimated using a random effects model. Meta-regression of prognostic factors was performed using individual patient data.
Twenty studies (2130 patients) were included. Initial management strategies at diagnosis were: surgery (27.3%), stereotactic radiosurgery (22.0%) and active monitoring (50.7%) with a weighted mean follow-up of 49.5 months (SD = 29.3). The definition of meningioma growth and monitoring regimens varied widely impeding relevant meta-analysis. The pooled risk of symptom development in patients actively monitored was 8.1% (95% CI 2.7-16.1). Associated factors were peritumoral edema (OR 8.72 [95% CI 0.35-14.90]) and meningioma diameter ≥ 3 cm (OR 34.90 [95% CI 5.17-160.40]). The pooled proportion of intervention after a duration of active monitoring was 24.8% (95% CI 7.5-48.0). Weighted mean time-to-intervention was 24.8 months (SD = 18.2). The pooled risks of morbidity following surgery and radiosurgery, accounting for cross-over, were 11.8% (95% CI 3.7-23.5) and 32.0% (95% CI 10.6-70.5) respectively. The pooled proportion of operated meningioma being WHO grade I was 94.0% (95% CI 88.2-97.9).
The management of incidental meningioma varies widely. Most patients who clinically or radiologically progressed did so within 5 years of diagnosis. Intervention at diagnosis may lead to unnecessary overtreatment. Prospective data is needed to develop a risk calculator to better inform management strategies.
偶然发现占新诊断颅内脑膜瘤的 30%。对于其最佳的管理方法尚无共识。本综述旨在评估这些肿瘤不同治疗策略的结果。
使用既定的系统综述方法,对截至 2017 年 9 月的六个数据库进行了扫描。使用随机效应模型估计合并事件比例。使用个体患者数据对预后因素进行了元回归分析。
共纳入 20 项研究(2130 例患者)。诊断时的初始治疗策略为:手术(27.3%)、立体定向放射外科治疗(22.0%)和主动监测(50.7%),平均随访时间为 49.5 个月(SD=29.3)。脑膜瘤生长和监测方案的定义差异很大,妨碍了相关的荟萃分析。主动监测患者症状发展的风险为 8.1%(95%CI 2.7-16.1)。相关因素为瘤周水肿(OR 8.72 [95%CI 0.35-14.90])和脑膜瘤直径≥3cm(OR 34.90 [95%CI 5.17-160.40])。主动监测后干预的合并比例为 24.8%(95%CI 7.5-48.0)。加权平均干预时间为 24.8 个月(SD=18.2)。手术和放射外科治疗后的发病率风险(考虑交叉)分别为 11.8%(95%CI 3.7-23.5)和 32.0%(95%CI 10.6-70.5)。接受手术的脑膜瘤中,世界卫生组织分级为 I 级的比例为 94.0%(95%CI 88.2-97.9)。
偶然发现脑膜瘤的管理方法差异很大。大多数临床或影像学进展的患者在诊断后 5 年内出现进展。诊断时的干预可能导致不必要的过度治疗。需要前瞻性数据来开发风险计算器,以更好地为管理策略提供信息。